These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36601632)

  • 1. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.
    Oliveira LJC; Megid TBC; Rosa DD; Magliano CADS; Assad DX; Argolo DF; Sanches SM; Testa L; Bines J; Kaliks R; Caleffi M; de Melo Gagliato D; Sahade M; Barroso-Sousa R; Corrêa TS; Shimada AK; Batista DN; Musse Gomes D; Cesca MG; Gaudêncio D; Moura LMA; de Araújo JAP; Katz A; Mano MS
    Ther Adv Med Oncol; 2022; 14():17588359221141760. PubMed ID: 36601632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature.
    Mooghal M; Khan MAA; Samar MR; Shaikh H; Valimohammad AT; Idrees R; Abdul Rashid Y; Sattar AK
    Breast Cancer (Auckl); 2024; 18():11782234241255211. PubMed ID: 38779417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
    Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
    Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
    Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
    Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of genomic profiling in early breast cancer in Colombia.
    Rojas L; Rojas-Reyes MX; Rosselli D; Ariza JG; Ruiz-Patiño A; Cardona AF
    Cost Eff Resour Alloc; 2023 Jul; 21(1):42. PubMed ID: 37430303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
    Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
    Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
    Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
    Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
    Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
    J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification.
    Ünal Ç; Özmen T; İlgün AS; Ordu Ç; Özkurt E; Ak N; Alço G; Erdoğan İyigün Z; Kurt S; Duymaz T; Öztürk MA; Elbüken Çelebi F; Yararbaş K; Soybir G; Aktepe F; Özmen V
    Breast Cancer (Dove Med Press); 2023; 15():659-669. PubMed ID: 37674872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
    Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
    Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX
    Turner BM; Finkelman BS; Hicks DG; Numbereye N; Moisini I; Dhakal A; Skinner K; Sanders MAG; Wang X; Shayne M; Schiffhauer L; Katerji H; Zhang H
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
    Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
    Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.